Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient. Issue 5 (6th May 2020)

• Record Type: Journal Article
• Authors: Dolan, Russell D.; Bazarbashi, Ahmad Najdat; Lo, Amy; Smith, Benjamin N.
• Is Part Of: ACG Case Reports Journal. Volume 7:Issue 5(2020)
• Page Start: e00380
• Publication Date: 2020-05-06
• DOI: 10.14309/crj.0000000000000380
• Languages: English
• ISSNs: 2326-3253

Abstract

ABSTRACT: Liraglutide is a glucagon-like peptide 1 (GLP-1) analog with a primary effect of increased glucose-dependent insulin secretion and decreased gastric emptying. It serves as a feasible medical weight loss option because of the drug's effect of invoking satiety and lowering caloric intake. Despite emerging efficacy, the GLP-1 class has been associated with severe, although rare, adverse events, including pancreatitis. Previous investigations demonstrated the greatest association between GLP-1 agonist-associated pancreatitis in diabetic populations; however, liraglutide dosing is higher in weight loss formulations, placing the weight loss population at higher risk. We present a case of liraglutide-induced acute pancreatitis in a patient without diabetes.